secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001193125-22-005038
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum doses first patient in Phase 1b of FTX-6058; cash $218.2M; appoints Kate Haviland as Chair
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities of $218.2M as of Dec 31, 2021 (unaudited), sufficient into 2024.
- First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; initial data expected Q2 2022.
- IND submitted for FTX-6058 to start Phase 1b in select hemoglobinopathies (beta-thalassemia) in Q2 2022.
- Update on losmapimod Phase 3 plan for FSHD expected in Q1 2022; no new data yet.
- Kate Haviland appointed Chair of board; Mark Levin resigns effective April 18, 2022 (no disagreement).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/0001193125-22-005038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522005038/d157429d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-005038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer